ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
NameBioPanel/s
2
Frances Acosta <fuentz118@gmail.com>After graduating from UP Diliman, BS MBB Frances spent a few years as a University Research Associate in NIMBB and UP MSI. After that, she joined the pharmaceutical industry and spent thirteen years Global and Regional Asia-Pacific roles involving Clinical Research, Quality and Training and Learning and Development.
She has been involved in vaccine clinical research studies locally and international as a CRA and Quality manager. She has facilitated internal audits and regulatory inspection with the USFDA, EMA, Phil and Thai FDA. Currently, she is the president of the Molecular Biology and Biotechnology Diliman Foundation.
Ethics & Regulatory
3
Manny Bacolod <mannybacolod@yahoo.com>Manny is an Assistant Professor of Microbiology and Immunology at Cornell’s Medical College (Weill) in New York City. A graduate of University of the Philippine’s Molecular Biology and Biotechnology undergraduate program, he went on to earn his Ph.D. in Chemistry from the University of Connecticut. Manny has held various research and academic positions at Duke University’s Brain Tumor Center, Weill Cornell Medical College, Brigham and Women’s Hospital (Harvard), and Virginia Commonwealth University’s Institute of Molecular Medicine. Among Manny's research interests is the integration of various genome-wide transcription, methylation, and chromatin datasets for various tissues and cell lines, to identify molecular biomarkers, and study pathways and epigenetic regulation related to immune infiltration in cancer.Immunology, Computational Biology / Bioinformatics
4
Marilen Balolong <mpbalolong@up.edu.ph>Lhen has a doctorate degree in public health specializing in applied medical microbiology and immunology. She had her post-doctoral training in KOREA on industrial microbiology and biotechnology where she did projects on functional food development, epitope mapping and antigen delivery design for viral pathogens (rotavirus and PEDV). As an ASEAN Science Diplomat, she is part of a regional body pushing for science diplomacy. Returning home, she is now a Professor and a University Scientist of the University of the Philippines Manila and leads the Applied Microbiology for Health and Environment Research group, a team advocating for One Health and Planetary health in helping resolve sustainable development goals. Their current work and initiatives in the pipeline on virology include functional food development for adjunct therapy for HIV-associated metabolic complications, pandemic zoonosis and wildlife trade, computer-assisted drug discovery for SARS-COV-2, wastewater epidemiology for virus surveillance and gut microbiome-based diagnostics for COVID19.Virology
5
Nini Cajimat <nbcajirm@utmb.edu>Nini (Maria) started her research at Research Institute for Tropical Medicine (RITM) investigating HIV-1/HCV/HBV, but got interested in emerging zoonoses while working with the veterinary research department under Dr. Elizabeth Miranda. She pursued her PhD at the University of Texas Medical Branch (UTMB) studying genetic relationships of rodent-borne arenaviruses and hantaviruses, and development of small animal models of disease (mice, rats, hamsters). Work with emerging zoonoses requires high containment facility and training and Nini has 15+ years of experience at biosafety level 3 and animal BSL3 and 5+ years of BSL4/ABSL4 (Ebola, CCHFV, hemorrhagic fever arenaviruses). Nini is a staff scientist at the Galveston National Laboratory - her service work includes maintenance of BSL4 virus collection and production of reagents (stock viruses, antigens, antisera) and her research work involves testing antiviral activities of peptide fusion inhibitors against Ebola, CCHFV, and coronaviruses MERS and SARS-CoV-2 in tissue culture and animals. Nini has trained under Drs. Charles Fulhorst and Thomas Ksiazek, both veterinarians and public health scientists at Viral Special Pathogens Branch, CDC prior to joining UTMB. She is skilled at working with unknown/emerging pathogens and establishing protocols for safe manipulation of these viruses. Lastly, Nini trains students and postdocs in containment work at BSL3 and BSL4.Virology
6
Salvador Caoili <seccaoili@yahoo.com>Badong conducted undergraduate thesis research on the production of monoclonal antibodies against dengue virus serotype 1 at the University of the Philippines (UP) Diliman. After earning his medical degree at the College of Medicine, UP Manila, he joined the teaching staff there at the Department of Biochemistry and Molecular Biology. He subsequently conducted doctoral dissertation research on computational tools for vaccine design and related biomedical applications, in part as a guest researcher at the US Centers for Disease Control and Prevention (CDC), to earn his PhD from UP Diliman. He also served as a core group member of the Ethical, Legal, Social Issues (ELSI) Program of the Philippine Genome Center (PGC) and a program development associate to the UP Technology Transfer and Business Development Office (TTBDO); and he is a founding core faculty member of the MD-PhD (Molecular Medicine) Program at UP Manila.Immunology, Ethics and Regulatory, Diagnostics, Computational Biology / Bioinformatics, Diagnostics
7
Francis Chung <fchu008@yahoo.com>Francis did his PhD in Pharmacology at the University of Auckland, Department of Molecular Medicine and Pathology. After two postdoc stints, in PeterMac Cancer Centre, Australia and the University of Washington, Seattle, he went back to the Philippines as a longterm Balikscientist. He established cell-based therapy labs at the Lung Center of the Philippines and Makati Medical Center whilst teaching at the Department of Biochemistry UPM College of Medicine. As a coinvestigator, Francis was involved in various clinical studies focusing on immunology-based therapy, namely cancer and auto-immune diseases from 2008 to 2015. He also served as a resource person at the DOH to assist in drafting the guidelines for cell-based therapy in the Philippines. Currently, he resides in New Zealand and affiliated with New Product Development Department, Douglas Pharmaceutical Ltd. He is knowledgable in formulation screening, method development, validation and stability studies. Francis divides his time doing research and supporting the medical affairs for clinical studies.Immunology
8
Leslie Michelle Dalmacio <lmdalmacio@up.edu.ph>Dr. Leslie Michelle Dalmacio has a PhD in Molecular Biology and Biotechnology and is affiliated with the University of the Philippines Manila College of Medicine. She did a research fellowship at Novartis through the Next Generation Scientist Program. She has worked on hepatitis viruses and flaviviruses in terms of diagnostics development, drug discovery, and molecular epidemiology. Virology, Ethics & Regulatory
9
Romulo de Castro <jongi1@yahoo.com>Jong conducted postdoctoral studies in Caltech under Professor Paul H. Patterson who pioneered the maternal immune activation etiology of neuropsychiatric disorders; he investigated the role of the neuroimmune cytokines LIF and IL-6 in spinal cord injuries. Subsequently as (Senior) Scientific Curator of the Immune Epitope Database (IEDB), a priority project of the NIAID/NIH in vaccine discovery led by Professor Alessandro Sette, Jong examined and curated complex, context-dependent human and animal immune responses to Categories A-C pathogens, emerging and reemerging infectious diseases and autoimmunity. Lastly and more recently, under his own start-up company 3R Biosystems, Jong has been investigating and discovering the different immune responses elicited in different cohorts of human cancers.Immunology
10
Amie Estacio <amie.estacio@gmail.com>For the past years, Amie has been actively conducting research on the therapeutic benefits of various indigenous substances from the Philippines like propolis and honey, berries, fruits, legumes and specific compounds for their neuroprotective, anti-inflammatory and cardioprotective properties employing various in vitro assay and in vivo animal models to test for their efficaciousness. Her 4-year collaborative research with the University of Tokyo led to the discovery of the anti-cancer activity of the Philippine stingless bee propolis. She is continuing this collaboration to identify novel compounds accountable for this anti-cancar activity. She is also engaged in developing biomedical products like gamma-radiated wound dressings and hemostatic agents through her collaboration with the Philippine Nuclear Institute (PNRI), Department of Science and Technology.Veterinary Medicine / Animal Science
11
Neil Tan Gana <nhtangana1@up.edu.ph>Neil completed a Ph.D. in Medical Sciences with an emphasis on Cellular and Molecular Biology (2014) from the Nagoya City University Graduate School of Medical Sciences as a Japan Government MEXT scholarship recipient. His research was in HIV-1 host-pathogen interaction systems in the non-coding RNA context. He also trained in bioinformatics, downstream next-generation sequencing, systems biology, and RNA interference.Virology
12
Nina Gloriani <ninagloriani@gmail.com>Dr Nina G. Gloriani is a public health graduate and a medical doctor from the University of the Philippines Manila, with a postgraduate degree (PhD) in Microbial Immunology from the University of Melbourne in Australia where she completed her dissertation at the Walter and Eliza Hall Institute of Medical Research. Her work focused on antigenic epitope analyses using synthetic peptides and cloned antigens, genetics of the immune responses, and immune evasion mechanisms. She also completed short term post-doctoral fellowships on serological and molecular analysis ofHCV infection, sexually transmitted diseases, molecular diagnostics in clinical microbiology, and CD4 function and CD antigen activation in HIV infection.
She is a retired Full Professor of Medical Microbiology and Immunology. From 2007 to 2013, she served as Dean of the College of Public Health (CPH), UP Manila, and concurrently, the Director of SEAMEO-TROPMED Regional Center for Public Health, Hospital Administration, Environmental and Occupational Health. From 1995-2005, she served as Director of the Institute of Biotechnology and Molecular Biology of the National Institutes of Health-Philippines, and from 1995 to 1998, as Chairman of the Department of Medical Microbiology of CPH. She established the Microbial Immunology Research Group which addressed sero-epidemiologic and molecular studies on a number of infectious disease agents such as hepatitis A, B, C and E, HIV, herpes and hantaan virus, and most recently, a five-year JICA and DOST-PCHRD funded program for the prevention and control of leptospirosis in the Philippines wherein her team developed the Leptovax vaccine against 4 Leptospirae serogroups/serovars prevalent in the Philippines. Her main research interests are vaccine development and clinical trials, development of diagnostic kits and studies on host immune responses against bacterial and viral infections. Currently, Dr Gloriani serves as a Clinical Microbiology consultant in the Institute of Pathology, St Luke’s Medical Center -QC. She also serves as the Chairperson of the DOST Vaccine Expert Panel for COVID19 Clinical Trials in the Philippines, and a member of the WHO Scientific Steering Committee for the COVID19 Solidarity Vaccines Trial.
As a practicing clinical microbiologist and advocate for the safe and responsible use of Biotechnology, Dr. Gloriani is an active member of various professional and scientific organizations: She served as President of the Biotechnology Coalition of the Philippines from 2007-2013, a Fellow of various medical and professional societies in Microbiology, Allergy and Immunology, Editor of the Southeast Asian Journal of Tropical Medicine and Public Health, and a member of the Editorial Board of the Philippine Journal of Allergy and Immunology and peer reviewer of Acta Medica Philippina. She continues to serve as the Chairperson of the National Certification Committee for the Eradication of Poliomyelitis in the Philippines (since 1997), and serves as technical consultant to various agencies in the fields of medical microbiology and microbial immunology, and medical biotechnology.
Virology, Biotech & Vaccine Production
13
Julius Hafalla <julius.hafalla@gmail.com>Julius is an Associate Professor of Immunology at the London School of Hygiene and Tropical Medicine. He has worked on the immunology and pathogen-host interactions of infectious diseases, particularly malaria and tuberculosis in the Philippines. Virology, Immunology
14
Frank Heralde <fmheralde@gmail.com>FRANCISCO M. HERALDE III is a Professor at the Department of Biochemistry and Molecular Biology, College of Medicine, University of the Philippines – Manila. He is a Visiting Consultant at the Lung Center of the Philippines-Molecular Diagnostics and Cellular Therapeutics Laboratory and the Principal Investigator of a DOST funded project on Metabolomics of Ampalaya and Garlic for Diabetes and Hypertension and co-investigator of the PITAHC funded project on the Establishing Philippine Blueprint for Nature-based Products. He obtained his PhD in Molecular Biology and Biotechnology at the University of the Philippines - Diliman in 2007; finished Masters in Business Administration at Wesleyan University of the Philippines-Manila in 2001; finished Master of Science in Biochemistry at UP Manila in 2000; and acquired a Bachelor of Science in Fish Processing Technology (Cum Laude) at UP Diliman in 1987. He also finished a Diploma in Product Research and Development in 2009 from Thammasat University, Thailand and a BS Nursing degree in Philippine College of Health and Sciences in 2010; and is a registered nurse. He has generated a number of publications including 17 peer-reviewed local and international publications. He was a NAST Awardee on Outstanding Scientific Paper in 2012 and a UP Manila Gawad Chancellor Awardee as Outstanding Researcher in 2012. His current research interests include metabolomics, molecular diagnostics, toxinology and cellular therapeutics.Immunology, Diagnostics, Computational Biology / Bioinformatics
15
Vic Ilag <vilag2001@yahoo.com>Vic was granted a PhD in Microbiology/Immunology from University of Tennessee Health Science Center under the tutelage of Nino L Incardona working on the DNA injection mechanism of bacteriophage phix174 using biochemical and genetic methods.
He was also a postdoctoral fellow with Michael G Rossmann at Purdue University studying the assembly and uncoating mechanisms of viruses using x-ray crystallography and cryoelectron microscopy.
Virology, Immunology, Biotech & Vaccine Production, Diagnostics
16
Hilton Lam <hylam@up.edu.ph>Dr. Hilton Yu Lam, MHA, PhD is an accomplished senior scientist and faculty member at the University of the Philippines Manila, where he is Director of the Institute for Health Policy and Development Studies (IHPDS). He is also the Consortium Director of the Metro Manila Health Research and Development Consortium (MMHRDC). As a health economist, Dr. Lam’s expertise is on the quantification of health outcomes and health-related phenomena, particularly on the cost-effectiveness of public health interventions as well as the financial burdens to society of infectious and chronic illness and emergency health situations. He is recognized by the University of the Philippines System as Professorial Chair in Health Economics and Policy. Dr. Lam’s record of accomplishments in these areas is notable, with 72 international publications and 22,477 citations, and is well regarded among his peers for rigorous health research that aims to benefit Philippines society. Dr. Lam earned his BA in Economics and BA in Biology from Whittier College, in USA, where he was a recipient of the John Greenleaf Whittier Scholarship; his Master in Hospital Administration from the University of the Philippines Manila College of Public Health, where he was a Dean’s Lister, and his PhD in Health Sciences with concentration in Health Economics from the University of Tokyo, with a Monbukagakusho research grant, and is a Fulbright Scholar Program Senior Scholar Awardee. Ethics & Regulatory, Epidemiology / Public Health
17
Daria Manalo <darsky1566@gmail.com>Dr. Daria L. Manalo is a veterinarian and a Chief Science Research Specialist of the Veterinary Research Department (VRD) of the Research Institute for Tropical Medicine (RITM), Department of Health She is a fellow of the Philippine College of Veterinary Public Health (PCVPH). She represented the Philippines in the workshop on the Veterinary Public Health and one of the Philippine representatives in the Southeast Asia Framework for Zika Virus Preparedness and Response. At the same time a member of the National Rabies Prevention Control Committee (NRPCC) and the Technical Working Group of the Animal Schistosomiasis in the Philippines. She developed a reagent for the Direct Rapid Immunohistochemical Test (DRIT) for rabies diagnosis in the Philippines and has on-going research on the sustainability of the reagents. And she is conducting training for the less invasive procedure of brain collection both for human and animal rabies diagnosis. She is a member of the Philippines Association of Laboratory Animal Science (PALAS) and a Diplomate of the Philippine College Laboratory Animal Medicine (PCLAM). Currently, she is the Chairman of the RITM Animal Care and Use Committee (IACUC) and veterinarian of IACUC UST, Manila. She contributed to the amendments of the Administrative Order 40 series of 1999 of the Animal Welfare Act of the Philippines and a trainer on the training of ethical use of laboratory animal in research. Virology, Veterinary Medicine / Animal Science
18
May Anne Mata <memata@up.edu.ph>Dr. May Anne E. Mata, also known as Mayang, started her journey in modeling biological systems as a PhD student at UBC Vancouver under the supervision of Dr. Leah Edelstein-Keshet, a Canadian-Israeli mathematician who authored three textbooks in the field of mathematical biology. In two years, she gained research experience on mathematical modelling with biochemical motifs as well as analysis and simulations of intracellular actin waves using differential equations. Prior to her transfer to UBC Okanagan where she was co-supervised by Dr. Rebecca Tyson and Dr. Priscilla Greenwood, she assisted in a diabetes modelling project where she investigated the effects of an anti-diabetic agent to glucose-insulin system via model fitting and parameter estimation. In Okanagan, she obtained additional research experience in modeling other biological systems specifically those used for understanding population ecology, biological pest control agents, host-pathogen relationships, and spread of infectious diseases. Mayang's PhD dissertation entitled “Avian influenza epidemic recurrence and approximate stochastic models” provides insight on understanding noisy oscillatory patterns observed in disease data as well as showcase novel analysis for a stochastic process that describes recurrent epidemics. Currently, her research focuses on application of mathematical models and statistical methods to study the spatio-temporal dynamics and patterns of various diseases in the country such as canine rabies and COVID-19.Epidemiology
19
Lyre Murao <lemurao@up.edu.ph>Lyre is a molecular virologist who trained at the University of Illinois Urbana-Champaign, USA for her MS Microbiology and Nagasaki University, Japan for her PhD on Medical Science in Infection Research where she worked primarily on virus-host interactions. She continued to pursue this field through a postdoctoral fellowship at Okapi Sciences NV, Belgium under the EUVIRNA Marie Curie Early Training Network where she worked with antiviral drug discovery and development for veterinary applications. Upon her return to the Philippines, Lyre pursued an academic career as an Associate Professor at the University of the Philippines Mindanao and established research engagements in the fields of virology and molecular biology. She is currently the Program Director of the Philippine Genome Center Mindanao and promotes multisectoral engagements that utilize omics and molecular biology to address the needs of the region.Virology
20
Homer Pantua <pantuah@gmail.com>Homer Pantua is a Principal Scientific Researcher and Research Operations Manager at the Department of Infectious Diseases at Genentech, a biotechnology company which pioneered the development of therapeutics from recombinant DNA technology. He has led both antiviral and antibacterial discovery efforts and now contributing as a virologist for Genentech’s COVID-19 exploratory research. Homer obtained his PhD in Biomedical Sciences from the University of Massachusetts Medical School and developed a patented technology on Virus-like particles as a vaccine platform for human and animal pathogens. He also received his DVM from the University of the Philippines Los Banos. He initially received infectious disease training at the Research Institute for Tropical Medicine in the Philippines. He has maintained his connection to the Philippines by being a Balik Scientist in 2011 and by founding BioAssets Corporation, a Veterinary Research and Diagnostic Company in 2014. He is currently the President and CEO of BioAssets Corporation and is leading the company's Research and Development efforts on veterinary diagnostics, vaccines and therapeutics. He is also a Project Team Leader of a DOST-supported project through the Business Innovation for Science and Technology which aims to bring a comprehensive and unified approach in addressing gaps in animal health in the Philippines. Homer is very passionate about developing transformative therapies and vaccines for infectious diseases in humans and animals.Virology, Biotech & Vaccine Production, Veterinary Medicine / Animal Science
21
Karsten Pilones <karstendoc@gmail.com>Karsten received his medical degree (INTARMED) from the University of the Philippines – Manila in 2001 and graduate training at the State University of New York (SUNY) Upstate Medical University in Syracuse NY where he received his PhD in Microbiology and Immunology in 2007. Shortly thereafter, he joined Sandra Demaria’s lab at NYU School of Medicine as a postdoctoral fellow in tumor immunology and immunotherapy. In 2009, he was awarded a 3-year postdoctoral fellowship from the US Dept of Defense CDMRP Breast Cancer Research Program to study the regulatory role of invariant natural killer T cells in anti-tumor immunity. He joined Weill Cornell Medicine in 2015 and is currently a research scientist in radiation oncology. He oversees several independent projects and collaborations to understand how radiation impacts anti-tumor immune responses and identify new opportunities for therapeutic partnerships that exploit the unique interaction of focal radiotherapy with immune responses modifiers.Immunology
22
Jonel Saludes <jsaludes@usa.edu.ph>Dr. Saludes earned his PhD in Organic Chemistry at UC Davis under Dr. Jacquelyn Gervay-Hague and used extensive NMR spectroscopy, mass spectrometry, and computational structural biology to demonstrate the stable structure of peptides that serve as biomarker of several human cancers. He was also a team member in the design and large scale synthesis of multivalent mimotopes as potential vaccine candidates for HIV. His postdoctoral training at University of Colorado under the supervision of Dr. Hubert Yin enriched his skills in designing synthetic peptides todetect exosomes involved in cell signaling. He pursued an independent academic career at Washington State University and developed ExoCAR, a peptide-based exosome capture technology and SialoPen, a new class of unnatural peptide-based drug delivery agent.
Currently, he is University of San Agustin’s Associate VP for Research and Global Relations where he established the Center for Chemical Biology and Biotechnology (C2B2) for life science and biotechnology research; Center for Natural Drug Discovery and Development (CND3), the home of Tuklas Lunas Center in Western Visayas; Center for Heritage and Indigenous Cultures (CHIC), the resource in the preservation and enrichment of Filipino culture, heritage, indigenous identity; and Center for Informatics (CFI), the first research center in the Philippine countryside solely dedicated to data analytics and medical and bio/chemoinformatics.
Biotech & Vaccine Production
23
Krista Serquiña <anna.serquina@nih.gov>Anna completed her medical degree (M.D., Intarmed) at the University of the Philippines College of Medicine. As a medical student, she was involved in recruiting participants to the INTERHEART study (PMID: 15364185) under the mentorship of Dr. Tony Dans. She earned her Ph.D. in Biomedical Sciences at the University of Massachusetts Medical School studying HIV-1 host-pathogen interactions (PMID: 19560422, 23785196). She went on to do her postdoctoral fellowship at the National Cancer Institute, National Institutes of Health in Bethesda, Maryland, working on host targets of viral microRNAs (PMID: 28698273, 30455306). In collaboration with clinical investigators studying Tocilizumab, she developed an assay to detect IL-6 from patient samples (PMID: 32276276 ). As the COVID-19 pandemic unfolded, she has given several webinars on SARS-CoV2, most recently discussing the status of COVID-19 vaccine research at the 17th Postgraduate Course of Manila Doctors’ Hospital. Anna is a newly-elected member of the Philippine American Academy of Science and Engineering (PAASE), and currently serves as Treasurer.Virology
24
Peter Sy <peter.sy@gmail.com>Peter Sy is a professional ethicist, consultant and teacher of bioethics for decades. A member of the eHealth TWG of the DOH/DOST/PhilHealth and chairman of its Privacy Experts Group, Associate Prof Sy has also led various research initiatives in data privacy, educational technologies, and bioethics, including "A Project to Rapidly Develop A Set of Ethics Guidelines on COVID-19 Hospital Care" (2020). He is Chair, Ad Hoc Committee on Open Data, University of the Philippines Diliman; Program Director (2011-2014), Ethical, Legal, Social Issues (ELSI) Program, Philippine Genome Center; Executive Officer (2003-2014), International Association of Bioethics (IAB); Research Fellow in Ethical Issues in International Research at the School of Public Health, Harvard University.Ethics & Regulatory
25
Willy Tan <wilbertan@gmail.com>Willy B. Tan, PhD, PMP, has over 15 years of experience in the biopharmaceutical industry (Wyeth/Pfizer). He started with post-doctoral work in the oncology discovery research group then moved into the formulation development group for vaccines. Willy then joined the manufacturing group to produce vaccine supplies for clinical trials. He later became a subject matter expert in the manufacturing science and technology group supporting several vaccines and other biotherapeutic products (Prevenar 13, Trumenba, Mylotarg, Besponsa, etc.). In this role, he was involved in ensuring drug product manufacturing process understanding, and has supported validation, investigations, technology transfers, process improvements, and registration of the products in the US, EU and other markets. Recently, he joined the Global Chemistry, Manufacturing and Controls group in Regulatory Affairs responsible for the initial submission of applications for new vaccines.

Willy has a BS in Molecular Biology and Biotechnology from the University of the Philippines and a PhD in Chemistry from the University of Connecticut. He has also done post-doctoral work at Wesleyan University. Additionally, Willy has a Graduate Certificate in Pharmaceutical Manufacturing from NJIT and is a Certified Project Management Professional.
Biotech & Vaccine Production
26
Gianne Eduard Ulanday <glulanday@up.edu.ph>Gianne is a medical technologist with specialized training in tropical medicine and molecular virology. Currently, he is heading the COVID-19 Task Force of the National Institutes of Health at UP Manila, in addition to his functions as a research faculty member of the same institution. Moreover, his microbiology and public health background provided him an opportunity to be involved in the training and site assessments of biomedical laboratories working on high-consequence pathogens. He holds a PhD in Medical Science and Postgraduate Diploma on Clinical Product Development for Public Health from Nagasaki University and a Master of Public Health (Tropical Medicine) from UP Manila. He has done work on recombinant viral proteins used to develop antiviral screening assays and virulence studies of newly-isolated viruses. His research interests revolve around emerging and re-emerging infectious diseases of significant public health concern. He is confident in working on novel pathogens, including patient samples, under high biocontainment. Dr. Ulanday is also registered as a Microbiologist with the Philippine Academy of Microbiology (PAM).Virology, Epidemiology / Public Health
27
John Mark Velasco <jsvelasco@up.edu.ph>Dr. John Mark Velasco earned his Bachelor of Science in Biology, Masters in Public Health, and Doctor of Medicine degrees from the University of the Philippines, and completed a certificate in emerging infectious disease epidemiology from the University of Iowa, a post-graduate diploma and Masters of Science in clinical trials from the London School of Hygiene and Tropical Medicine and a Diploma in Tropical Medicine and Hygiene from the Liverpool School of Tropical Medicine. Dr. Velasco is a research faculty under the Institute of Molecular Biology and Biotechnology of the Philippines National Institutes of Health and also a clinical associate professor under the Department of Clinical Epidemiology of the University of the Philippines College of Medicine. His research interests encompass various disciplines, including virology, emerging and re-emerging infections, emerging antibiotic resistance of multidrug-resistant organisms, clinical and molecular epidemiology, electronic disease surveillance/ infectious disease modelling, and clinical trials. Virology
28
Ann Villalobos <annpvillalobos@gmail.com>Ann has constantly worked for the design, optimization and best practices of biotech processes to deliver safe, efficacious and quality biopharm drugs at Johnson & Johnson for 18 years. A technical expert lead in a blockbuster drug EPREX®, Remicade® and Orthoclone OKT3®. She led process development and validation: removal/inactivation of model viruses: XMuLV, PRV, Reo-3 and MMV. She authored Quality Overall Summary (QOS) regulatory drug submissions for approval. Technical lead in face to face meetings with EU and US-FDA. Investigated a post approval formulation concern, PRCA in 0.005% patients receiving EPREX®. Received the Johnson & Johnson Standards of Leadership Award for contributions in solving PRCA. As DOST- PCHRD Balik Scientist, Ann conducted trainings for the Philippine FDA’s capability building on biotech drugs. She obtained her Ph.D. from the University of Cincinnati on protein structure mapping with monoclonal antibodies and a postdoctoral fellowship on Cell and Molecular Biology at the University of Pennsylvania. Ethics & Regulatory, Biotech & Vaccine Production
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100